# US 10,864,221 B1 · Neuroprotective mixture for mitigating the harmful effects of ischemic stroke

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,221 B1
- Document ID: US10864221B1
- Status: Granted
- Kind: B1
- Application number: 16/354,994
- Filed: 2019-03-15
- Granted: 2020-12-15
- Earliest claimed: 2018-07-07
- Assignees: Tricerapro Holding, LLC
- Applicants: Tricerapro Holding, LLC
- Inventors: Joseph L. Clark; Todd J. Crocco; Charles L. Rosen; Steven Cutright
- Web page: https://patentgrep.com/patent/US10864221B1

## CPC

- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 31/191: having two or more hydroxy groups, e.g. gluconic acid
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A neuroprotective mixture includes Phosphocreatine (PCr), Magnesium Gluconate (MgG), and β-hydroxybutyrate (BHB). The PCR, MgG, and BHB are combined in a 2:1:2 molar ratio of PCr:MgH:BHB. The neuroprotective mixture is a useful preventative and prophylactic supplement, which also can function to extend the post-stroke treatment window.

## Claims

### Claim 1

A method of mitigating the harmful effects of ischemic stroke in a person, comprising administering to that person a dietary supplement comprising a mixture of phosphocreatine, magnesium gluconate, and beta hydroxybutyrate in a 2:1:2 ratio, wherein the supplement is administered orally on a daily basis prior to the occurrence of a stroke to mitigate the harmful effects on the person of having a stroke.